Race Oncology Limited (“Race”) is pleased to announce an updated strategic plan designed to move its lead asset, reformulated bisantrene, RC220, through clinical studies that aim to build significant shareholder value within the constraints of current capital market conditions.

Highlights include:

● Updated corporate strategy focused on clinical development within Australia to achieve commercial goals using available resources

● Program designed to establish anthracycline cardioprotection and clinical effects on the m6 A RNA pathway using RC220 in a range of solid tumours

● Phase 1a/b trial fully funded from existing cash with a Bonus Option to reward loyal shareholders and fund Phase 2 efficacy studies in both solid tumours and AML.